Latest news with #Hims&Hers
Yahoo
6 hours ago
- Business
- Yahoo
Hims & Hers makes a big Europe push with an acquisition. Knockoff weight loss drugs could be next
Hims & Hers (HIMS) is expanding its playbook across the Atlantic — the U.S.-based telehealth company announced Tuesday that it will acquire European telehealth platform Zava. The acquisition grows Hims & Hers' presence in the U.K. and gives the company a foothold in Germany, France, and Ireland, marking the company's biggest international move to date. The terms of the deal weren't disclosed, but the translation is an all-cash one expected to close later this year. Hims & Hers stock was up over 17% Tuesday morning — and is up an astounding 165% year to date. The deal adds more than 1.3 million active users to the company's existing 2.4 million subscriber base and positions Hims & Hers to roll out its digital healthcare model in some of Europe's largest healthcare markets. Weight-loss drugs will likely be a central part of that expansion. Andrew Dudum, Hims & Hers' CEO, told The Financial Times that there's a 'huge opportunity' in obesity, noting that Zava already offers branded weight-loss treatments and has seen growing demand. Hims & Hers is perhaps best known in the U.S. for its direct-to-consumer offerings across categories such as hair loss, sexual health, and anxiety — but its compounded GLP-1 medications have become one of its fastest-growing offerings. The company, which recently struck a deal to offer Novo Nordisk's Wegovy, has been threading a regulatory needle: offering custom formulations to a 'meaningfully smaller group of patients,' as CEO Andrew Dudum put it to The Financial Times. With the Zava deal, similar offerings could be on the horizon for Europe. In the U.K., compounded medications can legally be dispensed under certain conditions, providing an opening for Hims & Hers' approach. Lower pharmaceutical prices and public health system constraints could accelerate adoption. And with U.S. compounding regulations tightening and the branded supply stabilizing, international expansion could create a path for further growth. This isn't Hims & Hers' first international foray — the company acquired London-based Honest Health in 2021 — but the Zava deal adds an established European presence and could position Hims & Hers to build a branded footprint in key European markets while leveraging Zava's infrastructure. 'Early traction in the U.K. gives us confidence that we can scale our platform globally,' Dudum said on his company's recent earnings call. Zava CEO and co-founder David Meinertz will remain on board as general manager of the international business, and the Zava brand will reportedly stay live for a few quarters before rebranding as Hims & Hers. Meinertz said the deal could help ease pressure on Europe's strained healthcare systems. 'The medications are priced more competitively than in the U.S., so more people can actually afford it, and we are seeing a huge demand,' Meinertz told CNBC. 'The demand is increasing with additional strains on the statutory systems that telehealth can alleviate.' Hims & Hers is betting on that growing pressure on national health systems. 'Whether in rural towns, vibrant cities, or remote communities across Europe, people battling widespread, often silent chronic conditions like obesity, depression, and more will have access to the personalized, high-quality care they deserve,' Dudum said in the company's press release. 'The demand for simpler, more personalized healthcare is universal.' For the latest news, Facebook, Twitter and Instagram. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Time of India
7 hours ago
- Business
- Time of India
Hims to acquire UK-based startup Zava as it expands international presence
New York: Telehealth platform Hims & Hers said on Tuesday it will acquire London-based startup Zava for an undisclosed amount, allowing it to launch its offerings in Germany, France and Ireland and reach more international patients. The move comes as Hims is adjusting to a regulatory ban in the United States on manufacturing mass copies of Novo Nordisk's popular weight-loss drug Wegovy, that took effect on May 22. Hims began offering copies of Wegovy in 2024, and saw a boost in its revenues, when the branded version of the highly in-demand drug was in shortage. Shares of the telehealth firm have dropped nearly 9% in the last two weeks. It recently entered into an agreement with Novo to help patients access brand-name Wegovy, and plans to enter the market for low testosterone and menopause treatments in pursuit of new growth opportunities. Hims did not provide financial terms of the deal, but a company spokesperson said these details will be shared with its second-quarter results expected in August. It plans to fund the acquisition through cash on its balance sheet at closing. The deal is expected to close in the second half of this year. Backed by equity firm HPE Growth, Zava provides medical consultations and delivery of prescription medicines - including weight loss drugs Mounjaro and Wegovy - to its more than 1 million customers across United Kingdom, Germany, France and Ireland. Hims said it plans to introduce personalized skin care, weight loss and other offerings for patients in these markets and will introduce an option for patients to interact with their healthcare providers in local languages. Last week, Hims also said it will cut about 4% of its workforce but still plans to hire for roles related to its long-term growth strategy.
Yahoo
10 hours ago
- Business
- Yahoo
Hims & Hers Expands in Europe With Acquisition of ZAVA
Hims & Hers expanding in Europe with the purchase of London-based digital health platform ZAVA. The acquisition gives the health and wellness site an increased reach in the U.K., and launches the firm in Germany, France, and Ireland. The price of the all-cash deal was not & Hers Health (HIMS) shares rose Tuesday after the health and wellness site announced it was expanding its reach into Europe by buying London-based digital health platform ZAVA. The price of the all-cash deal was not disclosed. Hims & Hers explained that the purchase will increase its presence in the U.K., and give the firm an entry into Germany, France, and Ireland, "with more markets anticipated soon." Founder and CEO Andrew Dudum said by leveraging ZAVA's "established European presence, cutting-edge technology, and deep customer understanding, we're poised to fundamentally transform access to care for millions across Europe." The company added that it would soon introduce "a new, personalized dimension of digital health in Europe, providing individuals with access to care tailored to their specific needs and goals across dermatology, weight loss, sexual health and mental health." Hims & Hers noted that the acquisition would be paid for from the company's balance sheet, and is expected to close in the second half of this year. It expects the addition of ZAVA to be accretive by next year. Shares of Hims & Hers advanced about 3% in recent trading and have soared about 130% this year. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
14 hours ago
- Business
- Business Wire
Hims & Hers Announces Plans to Acquire ZAVA, Accelerating Major European Growth Across the UK, Germany, France, and Ireland
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced a significant step in its global expansion through its agreement to acquire ZAVA, a leading digital health platform in Europe. This strategic move will expand Hims & Hers' footprint in the United Kingdom and will officially launch the company into Germany, France, and Ireland, with more markets anticipated soon. This acquisition is expected to accelerate Hims & Hers' vision to deliver the same seamless, personalized care experience it has successfully built in the U.S. to millions more people globally. Hims & Hers will establish its own branded presence, leveraging the robust ZAVA platform, in each of these European markets in the coming quarters. By combining ZAVA's trusted European operations, medical rigor, and seamless digital experience with Hims & Hers' proven, trusted brand, the company is poised to become a leader in digital health globally, delivering access to personalized care that meets people where they are. This strategic acquisition will significantly strengthen Hims & Hers' international footprint. Serving more than 1.3 million active customers, ZAVA's in-house medical team delivered nearly 2.3 million consultations in 2024 across the UK, Germany, France, and Ireland. Hims & Hers will soon introduce a new, personalized dimension of digital health in Europe, providing individuals with access to care tailored to their specific needs and goals across dermatology, weight loss, sexual health and mental health. To ensure a world-class and localized experience, this expansion will include access to British, German, and French healthcare providers in local languages. While Hims & Hers will share more about the offerings and their rollout in the coming months, they expect the deal to be accretive by 2026. 'The demand for simpler, more personalized healthcare is universal,' said Andrew Dudum, founder and CEO of Hims & Hers. 'By leveraging ZAVA's established European presence, cutting-edge technology, and deep customer understanding, we're poised to fundamentally transform access to care for millions across Europe. Whether in rural towns, vibrant cities, or remote communities across Europe, people battling widespread, often silent chronic conditions like obesity, depression, and more will have access to the personalized, high-quality care they deserve.' 'Wherever you live, the need is the same: healthcare that's personal, trustworthy and fast. By joining forces with Hims & Hers, we can put that standard within reach of millions more people across Europe,' said David Meinertz, co-founder and CEO of ZAVA. 'Together we'll pair ZAVA's trusted clinical services, established footprint, and deep understanding of the European healthcare landscape with the Hims & Hers experience to make affordable access to high-quality, personalized care the rule, not the exception. I'm thrilled to be working with Andrew and his team. It's still day one for digital healthcare, and I can't wait to see what we'll achieve for patients in the years ahead.' The acquisition consideration will be comprised of 100% cash, to be funded from the company's balance sheet at closing. The acquisition is expected to close in the second half of 2025, and Hims & Hers expects to continue expanding globally as demand for personalized healthcare continues to grow. For more information, please see About Hims & Hers Health, Inc Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That's why we're building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the company provides access to personalized care designed for results. For more information, please visit and About ZAVA ZAVA is a leading digital health platform in Europe, on a mission to make high-quality, dependable healthcare accessible and affordable. Serving more than 1.3 million active customers, ZAVA's in-house medical team delivered nearly 2.3 million consultations in 2024 across the UK, Germany, France and Ireland - putting compassionate, clinically-robust healthcare in people's hands 24/7. Rated 'outstanding' for leadership by the UK Care Quality Commission, ZAVA combines medical rigour with a friction-free digital experience. ZAVA's comprehensive service portfolio spans weight management, women's and men's health, sexual health, general medicine and skin & hair care - helping people tackle both everyday and sensitive conditions quickly, discreetly and safely. Cautionary Note Regarding Forward-Looking Statements Except for historical information, certain statements in this press release, including statements regarding the timing and effects of entering into the acquisition described above, our future performance, anticipated customer demand, the ability to scale our business, the solutions accessible on our platform, and the underlying assumptions with respect to the foregoing, are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, and are subject to risks, uncertainties and assumptions about Hims & Hers and its business. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties related to market conditions, our legal and regulatory environment, macroeconomic and geopolitical factors, and those factors described in the 'Risk Factors' section of each of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and any of our subsequent filings with the Securities and Exchange Commission (the 'Commission'). Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation (and expressly disclaim any obligation) to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. These risks and others described in the 'Risk Factors' section of each of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and any of our subsequent filings with the Commission may not be exhaustive.
Associated Press
14 hours ago
- Business
- Associated Press
Hims & Hers Announces Plans to Acquire ZAVA, Accelerating Major European Growth Across the UK, Germany, France, and Ireland
SAN FRANCISCO--(BUSINESS WIRE)--Jun 3, 2025-- Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced a significant step in its global expansion through its agreement to acquire ZAVA, a leading digital health platform in Europe. This strategic move will expand Hims & Hers' footprint in the United Kingdom and will officially launch the company into Germany, France, and Ireland, with more markets anticipated soon. This acquisition is expected to accelerate Hims & Hers' vision to deliver the same seamless, personalized care experience it has successfully built in the U.S. to millions more people globally. Hims & Hers will establish its own branded presence, leveraging the robust ZAVA platform, in each of these European markets in the coming quarters. This press release features multimedia. View the full release here: This strategic move will expand Hims & Hers' footprint in the United Kingdom and will officially launch the company into Germany, France, and Ireland, with more markets anticipated soon. By combining ZAVA's trusted European operations, medical rigor, and seamless digital experience with Hims & Hers' proven, trusted brand, the company is poised to become a leader in digital health globally, delivering access to personalized care that meets people where they are. This strategic acquisition will significantly strengthen Hims & Hers' international footprint. Serving more than 1.3 million active customers, ZAVA's in-house medical team delivered nearly 2.3 million consultations in 2024 across the UK, Germany, France, and Ireland. Hims & Hers will soon introduce a new, personalized dimension of digital health in Europe, providing individuals with access to care tailored to their specific needs and goals across dermatology, weight loss, sexual health and mental health. To ensure a world-class and localized experience, this expansion will include access to British, German, and French healthcare providers in local languages. While Hims & Hers will share more about the offerings and their rollout in the coming months, they expect the deal to be accretive by 2026. 'The demand for simpler, more personalized healthcare is universal,' said Andrew Dudum, founder and CEO of Hims & Hers. 'By leveraging ZAVA's established European presence, cutting-edge technology, and deep customer understanding, we're poised to fundamentally transform access to care for millions across Europe. Whether in rural towns, vibrant cities, or remote communities across Europe, people battling widespread, often silent chronic conditions like obesity, depression, and more will have access to the personalized, high-quality care they deserve.' 'Wherever you live, the need is the same: healthcare that's personal, trustworthy and fast. By joining forces with Hims & Hers, we can put that standard within reach of millions more people across Europe,' said David Meinertz, co-founder and CEO of ZAVA. 'Together we'll pair ZAVA's trusted clinical services, established footprint, and deep understanding of the European healthcare landscape with the Hims & Hers experience to make affordable access to high-quality, personalized care the rule, not the exception. I'm thrilled to be working with Andrew and his team. It's still day one for digital healthcare, and I can't wait to see what we'll achieve for patients in the years ahead.' The acquisition consideration will be comprised of 100% cash, to be funded from the company's balance sheet at closing. The acquisition is expected to close in the second half of 2025, and Hims & Hers expects to continue expanding globally as demand for personalized healthcare continues to grow. For more information, please see About Hims & Hers Health, Inc Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That's why we're building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the company provides access to personalized care designed for results. For more information, please visit and About ZAVA ZAVA is a leading digital health platform in Europe, on a mission to make high-quality, dependable healthcare accessible and affordable. Serving more than 1.3 million active customers, ZAVA's in-house medical team delivered nearly 2.3 million consultations in 2024 across the UK, Germany, France and Ireland - putting compassionate, clinically-robust healthcare in people's hands 24/7. Rated 'outstanding' for leadership by the UK Care Quality Commission, ZAVA combines medical rigour with a friction-free digital experience. ZAVA's comprehensive service portfolio spans weight management, women's and men's health, sexual health, general medicine and skin & hair care - helping people tackle both everyday and sensitive conditions quickly, discreetly and safely. Cautionary Note Regarding Forward-Looking Statements Except for historical information, certain statements in this press release, including statements regarding the timing and effects of entering into the acquisition described above, our future performance, anticipated customer demand, the ability to scale our business, the solutions accessible on our platform, and the underlying assumptions with respect to the foregoing, are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, and are subject to risks, uncertainties and assumptions about Hims & Hers and its business. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties related to market conditions, our legal and regulatory environment, macroeconomic and geopolitical factors, and those factors described in the 'Risk Factors' section of each of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and any of our subsequent filings with the Securities and Exchange Commission (the 'Commission'). Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation (and expressly disclaim any obligation) to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. These risks and others described in the 'Risk Factors' section of each of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and any of our subsequent filings with the Commission may not be exhaustive. View source version on CONTACT: Press Contact Susan Cadrecha [email protected] KEYWORD: CALIFORNIA IRELAND UNITED STATES FRANCE UNITED KINGDOM NORTH AMERICA EUROPE GERMANY INDUSTRY KEYWORD: HEALTH TELEMEDICINE/VIRTUAL MEDICINE FITNESS & NUTRITION GENERAL HEALTH VITAMINS/SUPPLEMENTS PHARMACEUTICAL SOURCE: Hims & Hers Copyright Business Wire 2025. PUB: 06/03/2025 07:15 AM/DISC: 06/03/2025 07:15 AM
